Fundraising Fox
Biomea Fusion
NASDAQ: BMEARedwood City, US · Founded 2017 · Delaware corporation · 58 employees on LinkedIn · 1 known investors
Find your way into Biomea Fusion
Sign up to see every warm intro you have to Biomea Fusion
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biomea Fusion team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biomea Fusion is a clinical-stage company developing oral small-molecule drugs for diabetes, obesity, and metabolic diseases, with lead programs including icovamenib, a menin inhibitor, and BMF-650, a GLP-1 receptor agonist.
Founders & leadership
Biomea Fusion was founded in 2017 by Thomas Butler and Ramses Erdtmann.
TB
Thomas ButlerCo-founder · Chief Executive Officer & Chairman of the Board2017–2025Thomas Butler holds an MBA in Finance from UCLA Anderson School of Management and brings biotech industry experience from roles at Gilead Sciences, where he contributed to hepatitis C and antiviral drug programs, and at Pharmacyclics, where he worked on the development and commercialization of oncology therapeutics.
RE
Ramses ErdtmannPresident, COO, Co-Founder and Board MemberRamses Erdtmann spent three decades in investment banking and financial services before moving into biotech, where he accumulated two decades of experience. He cofounded Biomea Fusion in 2017 and currently serves as President and Chief Operating Officer; previously, he spent seven years at Pharmacyclics building and overseeing finance, IT, HR, legal, and corporate affairs functions during its growth from 47 to 634 employees and subsequent $21 billion acquisition by AbbVie. He holds a Diplom Kaufmann in Finance and Banking from Westfaelische Wilhelms Universitaet in Muenster, Germany.
MJ
Michael J.M. HitchcockInterim Chief Executive Officer and Director
R(
Rainer (Ramses) ErdtmannPresident, COO, Co-Founder and Board MemberRainer Erdtmann has held leadership roles in biotech and finance, including 7 years at Pharmacyclics where he oversaw multiple departments and participated in major corporate transactions, and earlier investment banking experience at Commerzbank in Germany. He cofounded Biomea Fusion in 2017 and serves as its President and Chief Operating Officer, and holds a diploma in Finance and Banking from Westfaelische Wilhelms Universitaet Muenster.
Investors · 1
Reported raises · per SEC filings
Form D private placements$56M disclosed across 1 round · 2020
▶$56MraisedJan 2021 · 17 investors · BiotechnologyRule 506(b)
▶$56MraisedJan 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas ButlerExecutive Officer, Director
- Ramses ErdtmannDirector, Executive Officer
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Biomea Fusion.
In the news
Frequently asked questions
- What does Biomea Fusion do?
- Biomea Fusion is a clinical-stage company developing oral small-molecule drugs for diabetes, obesity, and metabolic diseases, with lead programs including icovamenib, a menin inhibitor, and BMF-650, a GLP-1 receptor agonist.
- Who founded Biomea Fusion?
- Biomea Fusion was founded by Thomas Butler, Ramses Erdtmann in 2017.
- Who are Biomea Fusion's investors?
- Biomea Fusion's investors include Aisling Capital.
- How much funding has Biomea Fusion raised?
- Biomea Fusion has disclosed $56M raised across 1 round.
- Where is Biomea Fusion headquartered?
- Biomea Fusion is headquartered in Redwood City, US.